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SUMMARY
Epithelial-mesenchymal transition (EMT) is a key step toward cancer metastasis, and Snail is a major
transcription factor governing EMT. Here, we demonstrate that Snail-induced EMT accelerates cancer
metastasis through not only enhanced invasion but also induction of immunosuppression.Murine and human
melanoma cells with typical EMT features after snail transduction induced regulatory T cells and impaired
dendritic cells in vitro and in vivo partly through TSP1 production. Although Snail+ melanoma did not respond
to immunotherapy, intratumoral injection with snail-specific siRNA or anti-TSP1 monoclonal antibody signif-
icantly inhibited tumor growth andmetastasis following increase of tumor-specific tumor-infiltrating lympho-
cytes and systemic immune responses. These results suggest that inhibition of Snail-induced EMT could
simultaneously suppress both tumor metastasis and immunosuppression in cancer patients.INTRODUCTION
Epithelial-mesenchymal transition (EMT) is a transdifferentiation
characterized by decreased epithelial markers such as E-cad-
herin and increased mesenchymal markers such as fibronectin
(Hay, 1995; Radisky, 2005). It is a dynamic process to acquire
cell motility with decreased adhesive ability for body organiza-
tion, including embryonic development and wound healing.
Currently, EMT is thought to be a key step for cancer metas-
tasis (Hugo et al., 2007; Radisky, 2005). Many EMT inducers
such as TGF-b (Peinado et al., 2003) and VEGF (Yang et al.,
2006) have been identified, and the molecular mechanisms
related to the highly invasive characteristics of cancer cells
have been intensively investigated (Huber et al., 2005; Radisky,
2005). Snail is a major transcription factor frequently upregu-
lated by various EMT inducers in a variety of cancers, while
EMT is regulated by many transcription factors such as Slug
and Twist. However, the interaction between cancer cells and
host immunity during EMT has not yet been evaluated. In thisstudy, we investigated the significance of Snail-induced EMT
for antitumor immune responses in hosts with progressive
cancers.
RESULTS
Establishment of Murine Melanoma Cell Lines
with EMT-like Features by snail Transduction
To evaluate interaction between immune cells and tumor cells
during EMT, we first established murine melanoma B16-F10
cells with EMT-like features after transduction with murine snail
cDNA using electroporation. Snail is one of the major transcrip-
tion factors governing EMT of various cancer cells, and its
increase in tumor tissues of patients is correlated with tumor
progression (metastasis and recurrence) in various cancers
including melanoma (Dissanayake et al., 2007; Kuphal et al.,
2005; Moody et al., 2005), hepatocellular carcinoma (Sugima-
chi et al., 2003), head and neck squamous cell carcinoma
(Yang et al., 2007), and endometrial cancers (Becker et al.,SIGNIFICANCE
Epithelial-mesenchymal transition (EMT) is considered to be an important step for cancer cells to metastasize. Its molecular
mechanisms have been intensively elucidated from aspects of cancer invasion, and Snail is thought to be amajor transcrip-
tion factor frequently involved in EMT in various cancers. Here, we demonstrate that Snail-induced EMT accelerates cancer
metastasis utilizing not only the enhanced invasive ability but also induction ofmultiple immunosuppression and immunore-
sistance mechanisms including immunosuppressive cytokines, regulatory T cells, impaired dendritic cells, and cytotoxic T
lymphocyte resistance. Snail blockade simultaneously inhibits both cancer invasion and themultiple immunosuppressions,
resulting in efficient inhibition of cancer metastasis. This strategy targeting EMT-regulating Snail may be useful for cancer
treatments, especially for immunotherapy, which should restore immunocompetence in patients.Cancer Cell 15, 195–206, March 3, 2009 ª2009 Elsevier Inc. 195
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Immunosuppression Induced by Cancers during EMT2007). It has been reported in melanoma that downregulation
of E-cadherin caused by Snail disrupts growth control by ker-
atinocytes and leads to melanoma progression (Herlyn et al.,
2000). After G418 selection, four clones were evaluated for
EMT characteristics. Although snail was slightly expressed in
the parental B16-F10 cells or B16-F10 cells mock-transfected
with empty vector, snail expression was markedly increased
in these Snail transfectants (Figures 1A and 1B). Along with
the snail increase, these clones showed EMT-like changes in
mRNA (Figure 1A) and protein expression (Figure 1B) and
cellular characteristics (Figure 1C) such as decreased E-cad-
herin (an epithelial maker) and increased fibronectin (a mesen-
chymal marker), spindle and dendritic shapes, decreased cell
proliferation, decreased cell adhesion, and increased cell inva-
sion as compared with the parental B16-F10 cells or mock
transfectants. Two Snail transfectants, E9-snail+ and H6-snail+
tumor cells, were selected for further studies due to having the
typical EMT-like characteristics. When these Snail transfec-
tants were implanted subcutaneously (s.c.) or intravenously
(i.v.) into C57BL/6 mice, the s.c. tumors grew slowly (Figure 1D),
more tumor cells metastasized to the lungs (Figure 1E),
and these mice showed decreased survival (Figure 1F) as
compared to mock tumor-implanted mice (significant differ-
ence, p < 0.01).
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Figure 1. snail-Transduced Murine Mela-
noma B16-F10 Cells with EMT-like Charac-
teristics
(A) Left: decrease of epithelial markers and
increase of mesenchymal markers in Snail trans-
fectants detected by RT-PCR. Right: the intensity
of snail, E-cadherin, and fibronectin was normal-
ized to GAPDH expression as a control.
(B) Decreased E-cadherin and increased fibro-
nectin in the Snail transfectants with spindle and
dendritic shapes (immunocytochemistry; scale
bars = 0.5 mm).
(C) Decreased proliferation and adhesion and
increased invasion of Snail transfectants (n = 3,
mean ± SD).
(D) Suppressed growth of Snail transfectants
in vivo. C57BL/6 mice were implanted subcutane-
ously (s.c.) with tumor cells (n = 5, mean ± SD).
(E) Enhanced in vivo metastatic ability of Snail
transfectants. Mice were implanted intravenously
(i.v.) with tumor cells, and the numbers of nodules
in lungs of the mice were counted on day 14 after
tumor implantation (n = 5, mean ± SD).
(F) Decreased survival of mice with Snail transfec-
tants. Mice were implanted i.v. with tumor cells.
Data shown in each panel are representative of
four independent experiments.
Induction of Immunosuppressive
CD4+Foxp3+ Cells by snail-
Transduced Melanoma Cells
Using these Snail transfectants with EMT-
like characteristics, we examined how
EMT would influence immune responses.
When spleen cells (SPCs) were cultured
with Snail+ tumor cells for 5 days, SPC
proliferation was decreased (p < 0.03; Figure 2A), and both
CD4+ and CD8+ cells were decreased in the culture (Figure 2B)
as compared to SPCs cultured with Snail parental or mock-
transfected tumor cells. Although CD4+CD25+ cells including
immunosuppressive naturally occurring regulatory T (nTreg) cells
were not increased in the culture, Foxp3, a master transcription
factor for immunosuppressive function of nTreg cells, was signif-
icantly induced in the CD4+CD25 cells as compared with those
cultured with Snail tumor cells (p < 0.017; Figure 2C; see also
Table S1 available online). Other molecules such as CTLA-4,
HO-1, granzyme B, and PD-1 expressed in CD4+CD25+ nTreg
cells were also expressed in the H6-stimulated CD4+ cells as
well as nTreg cells (Figure S1). To determine whether these
immunosuppressive cascades were caused by Snail expres-
sion, siRNAs specific for murine snail were transfected into the
H6-snail+ tumor cells. Along with downregulation of snail
expression, cell invasion and the ability to induce CD4+Foxp3+
cells were significantly decreased in H6-snail+ tumor cells by
snail-specific siRNA transfection as compared with cells trans-
fected with the scramble oligonucleotide control (Figures S2A–
S2D). The snail-specific siRNA #2was also effective in suppress-
ing snail expression in H6-snail+ tumors implanted s.c. into mice
by intratumoral injection (Figure S2E). These data confirm the
essential role of snail in tumor cells for Treg-like CD4+Foxp3+196 Cancer Cell 15, 195–206, March 3, 2009 ª2009 Elsevier Inc.
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Immunosuppression Induced by Cancers during EMTcell induction as well as cell motility. To evaluate suppressive
activity of the CD4+ cells cocultured with tumor cells, CD4+ cells
were separated from thecultureandadded toaTcell proliferation
assay, where fresh splenic CD4+ or CD8+ cells were stimulated
with anti-CD3 monoclonal antibody (mAb) and irradiated SPCs
asantigen-presenting cells (APCs) for 5days. TheCD4+cells pre-
cultured with H6-snail+ tumor cells significantly suppressed
proliferation of T cells, particularly CD8+ T cells, as compared
with the CD4+ cells precultured with Snail tumor cells (p <
0.001; Figure 2D). The induction of such immunosuppressive
CD4+Foxp3+ cells was also observed when SPCs were cultured
with the other Snail transfectants or the culture supernatants,
although their efficacies were lower than those of E9-snail+ and
H6-snail+ tumor cells having higher Snail expression (data not
shown). These results indicate that Snail+ B16-F10 cells in EMT
generate immunosuppressive CD4+Foxp3+ cells.
TGF-b, IL-10, and thrombospondin-1 (TSP1) have been
reported to induce Treg cells (Futagami et al., 2007; von
Boehmer, 2005; Crawford et al., 1998). We examined whether
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Figure 2. Induction of Immunosuppressive
CD4+Foxp3+ Cells by Snail+ Tumor Cells
(A) Inhibition of splenic cell proliferation by Snail
transfectants. Spleen cells (SPCs) were cocultured
with tumor cells for 5 days (n = 3, mean ± SD).
(B) Inhibition of T cell induction in the SPC culture
by Snail transfectants. The percentage of CD4+
or CD8+ cells was analyzed by flow cytometry.
(C) Foxp3 induction in the CD4+ cells of SPCs by
coculture with Snail transfectants. The percentage
of Foxp3+ cells was analyzed after gating CD4+
cells (upper row), CD4+CD25+ cells (middle row),
or CD4+CD25 cells (lower row) by flow cytometry.
(D) Immunosuppressive activity of the CD4+ cells
stimulated with Snail transfectants. Bulk SPCs
were cocultured with tumor cells for 5 days, and
CD4+ cells purified from the culture were tested
for immunosuppressive activity on T cell prolifera-
tion in response to anti-CD3 monoclonal antibody
(mAb) (n = 3, mean ± SD).
(E) Production of regulatory T (Treg)-inducible
cytokines from Snail transfectants. Tumor super-
natants cultured for 3 days were tested for each
cytokine using ELISA (n = 3, mean ± SD).
(F) Suppression of Foxp3 induction in CD4+ cells
by mAb addition to Snail transfectants. The
percentage of Foxp3+ cells was analyzed after
gating CD4+ cells by flow cytometry.
(G) Foxp3 induction in CD4+ cells cocultured with
B16-F10 tumor cells with increased Snail along
with high invasive ability after cytokine treatment
(tumor invasion: n = 3, mean ± SD). mRNA expres-
sion of snail, E-cadherin, and TGF-b was detected
by RT-PCR. The percentage of Foxp3+ cells was
analyzed after gating CD4+ cells by flow cytometry.
Data shown in each panel are representative of
three independent experiments.
these cytokines would be involved in the
CD4+Foxp3+ cell induction by Snail+
melanoma. Production of TGF-b and
TSP1, but not IL-10, was significantly
greater in Snail+ melanoma cells than in
Snail melanoma cells (p < 0.05; Figure 2E). The specific
mAbs, particularly anti-TSP1 mAb, markedly inhibited Foxp3
induction in CD4+ cells of SPCs cocultured with H6-snail+ tumor
cells (Figure 2F). Anti-TSP1 mAb was also effective in suppress-
ing CD4+Foxp3+ Treg induction caused by the parental B16-F10
melanoma (Foxp3+ cells in the CD4+ cells cocultured with mock
transfectant: 23% for mIgG versus 15% for anti-TSP1 mAb). The
inhibitory efficacy of the anti-TSP1 mAb on the H6-induced Treg
generation was statistically significant compared to that of the
control mIgG (p < 0.047; Table S1). These results indicate that
TSP1 is a potent mediator involved in the Treg induction caused
by Snail+ melanoma cells.
We further examined whether tumor cells with increased Snail
during naturally occurring EMT would induce Treg cells. When
B16-F10 (mock tumor) cells were treated with TGF-b or TNFa
for 3 days, expression of both snail and TGF-b was enhanced in
the tumor cells, along with reduced E-cadherin and augmented
invasive ability (Figure 2G). Foxp3 was increased in CD4+ cells
when cocultured with these tumor cells for 5 days (Figure 2G).Cancer Cell 15, 195–206, March 3, 2009 ª2009 Elsevier Inc. 197
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Immunosuppression Induced by Cancers during EMTInterestingly, TSP1 similarly caused these phenomena, indi-
cating that TSP1 couldbe also anEMT inducer, perhaps bymedi-
ating through TGF-b induction and activation as reported. These
results suggest that Treg cells can be induced by Snail+ tumors
during naturally occurring EMT in melanoma. TGF-b and TSP1
fromsuch tumors couldbepartly responsible for bothTreg induc-
tion and the further enhancement of EMT in an autocrinemanner.
Treg Induction Mediated by Immunosuppressive
CD11c+ Dendritic Cells Generated by Snail+
Melanoma Cells
We next examined whether CD4+Foxp3+ Treg cells would be
induced directly by Snail+ melanoma cells or indirectly via other
immune cells such as APCs. Foxp3 was increased in purified
CD4+ T cells by coculture with H6-snail+ tumor cells and was
augmented by addition of purified CD11c+ splenic cells
(Figure 3A, lower panels). However, the effect was reduced
whenCD4+cellswere separatelyculturedwithCD11c+cells using
transwell chambers, indicating requirement of cell-cell contact
among CD4+ cells, CD11c+ cells, and Snail+ tumor cells for
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Figure 3. Involvement of Immunosuppres-
sive CD11c+ Cells in CD4+Foxp3+ Cell
Induction
(A) Enhancement of Foxp3 induction in CD4+ cells
cocultured with H6-snail+ tumor cells in the pres-
ence of CD11c+ cells.
(B) Requirement of cell-cell contact among CD4+
cells, H6-snail+ tumor cells, and CD11c+ cells for
Treg induction. CD4+ cells were separately
cultured with H6-snail+ tumor cells or CD11c+ cells
using transwell chambers.
(C) Generation of CD11c+I-Ab+ cells with low CD80
and high IDO expression by coculture with H6-
snail+ tumor cells.
(D) Immunosuppressive activity of H6-stimulated
CD11c+ cells on T cell proliferation. CD11c+ cells
from bone marrow were stimulated with granulo-
cyte macrophage colony-stimulating factor (GM-
CSF) and tumor cells for 6 days, and these cells
were added to fresh CD4+ or CD8+ T cells with
anti-CD3 mAb (n = 3, mean ± SD).
(E) Foxp3 induction in CD4+ cells by coculture with
H6-prestimulated CD11c+ cells. The percentage of
Foxp3+ cells was analyzed after gating CD4+ cells
by flow cytometry.
(F) Generation of Treg-inducible CD11c+ cells by
TSP1 stimulation. CD11c+ cells from bone marrow
were stimulated with TSP1 with or without the IDO
inhibitor 1-methyltryptophan (1MT) in addition to
GM-CSF for 6 days and were analyzed for IDO
expression by flow cytometry. Fresh CD4+ T cells
were cocultured with these CD11c+ cells with
anti-CD3 mAb and analyzed for Foxp3 expression
after gating CD4+ cells by flow cytometry.
Data shown in each panel are representative of two
independent experiments.
optimal Treg induction (Figure 3B). These
results indicate that CD11c+ cells mediate
Treg induction by Snail+ melanoma cells.
We further examined the effects of
Snail+ melanoma cells on CD11c+ cells.
CD11c+ cells enriched from bone marrow cells (BMCs) were
cultured with tumor cells in the presence of granulocyte macro-
phage colony-stimulating factor (GM-CSF) for 6 days. When
CD11c+ BMCswere culturedwith Snailmelanoma cells, almost
all of the cells were differentiated intomature dendritic cells (DCs)
with high expression of I-Ab and CD80 (Figure 3C). These cells
induced proliferation of both CD4+ and CD8+ splenic T cells
(Figure 3D). In contrast, when culturedwithH6-snail+ tumor cells,
CD11c+ BMCs were differentiated into possibly regulatory DCs
with low expression of I-Ab and CD80 and high expression of
the immunosuppressive enzyme indoleamine 2,3-dioxygenase
(IDO) (Figure 3C). The T cell proliferative activity of these DCs
was significantly less than that of DCs cultured with mock trans-
fectant (p < 0.03; Figure 3D). In addition, Foxp3 increase was
observed in the CD4+ cells stimulated with the H6(+) CD11c+
BMCs (Figure 3E). These results indicate that Treg cells are
induced partly by impaired DCs generated by Snail+ tumor cells.
TSP1 is also known to be a negative regulator of DC functions
(Doyen et al., 2003). We examined whether TSP1 would be
involved in the DC impairment induced by Snail+ tumor cells198 Cancer Cell 15, 195–206, March 3, 2009 ª2009 Elsevier Inc.
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Figure 4. Resistance of Snail+ Melanoma to Immunotherapy
(A) H6-snail+ melanoma growth is not inhibited by immunotherapy with
cryoablation of tumors followed by intratumoral (i.t.) injection of gp70
peptide-pulsed dendritic cells (DCs) (CA/DC-IT; n = 5–7, mean).
(B) No increase in infiltration of gp70 tetramer-binding CD8+ T cells was
detected in H6-snail+ tumor tissues on day 7 after the therapy. The percentage
of each positive fraction was analyzed by flow cytometry. The numbers in
parentheses indicate the gp70 tetramer mean fluorescence intensity (MFI) of
gp70 tetramer-binding CD8+ cells.
(C) No proliferation of splenic T cells from mice with H6-snail+ tumors is
observed even after CA/DC-IT therapy. CD4+ or CD8+ cells purified from
SPCs of these mice were stimulated with anti-CD3 mAb and antigen-present-
ing cells (APCs) for 5 days (n = 3, mean ± SD).
(D) Resistance of H6-snail+ tumor cells to killing by gp70-specific cytotoxic
T lymphocytes (CTLs) (n = 3, mean ± SD). CTLs were induced using
SPCs from F10-mock(+) mice receiving CA/DC-IT therapy. White circles indi-
cate% specific lysis of mock-transfected tumor cells. Black circles indicate%
specific lysis of H6-snail+ cells.
Data shown in each panel are representative of two independent experiments.as well as Treg induction. TSP1-pretreated CD11c+ cells
increased Foxp3 in CD4+ cells when cocultured (Figure 3F).
When mAbs specific for TSP1 or TSP1 receptors (CD36 or
CD47) expressed on DCs were added to the CD11c+ cell culture
with TSP1, Treg induction was decreased (Figure S3A), suggest-
ing that Treg induction could be partly mediated by immunosup-
pressive DCs generated by TSP1 from Snail+ tumor cells. In the
TSP1-treated CD11c+ cells, however, IDO expression was
enhanced only slightly. Also, Treg induction was not completely
inhibited despite almost complete absence of IDO expression in
CD11c+ cells treated with the IDO inhibitor 1-methyltryptophan
(1MT). These results suggest that IDO is not significantly involved
in the Treg induction by TSP1-treated CD11c+ cells.
Resistance of Snail+ Melanoma to Immunotherapy
Next, the susceptibility of Snail+ melanoma to immunotherapy
was evaluated. H6-snail+ tumor cells implanted s.c. into
C57BL/6 mice grew significantly less than the mock-transfected
tumor cells (p < 0.001; Figure 4A). Immunotherapy with cryoabla-
tion of tumors followed by intratumoral (i.t.) injection of DCs
pulsed with tumor antigen gp70/H-2Kb peptide (CA/DC-IT)
significantly inhibited growth of mock-transfected tumors, but
not H6-snail+ tumors in spite of their slower growth (p <
0.0001; Figure 4A). Although mock-transfected tumors disap-
peared in 4–5 of 7 mice treated, H6-snail+ tumors showed no
regression in the mice treated. The CA/DC-IT therapy greatly
increased infiltration of both gp70 tetramer-binding CD8+ cells
and CD4+ cells with low Foxp3 expression in mock-transfected
tumor tissues (Figure 4B) and also systemically in the regional
lymph nodes, spleens, and peripheral blood of the mice (Table
S2). However, only a small increase of T cell infiltration including
CD8+ cells with much lower gp70 tetramer binding and CD4+
cells with higher Foxp3 expression was observed in H6-snail+
tumors treated with the therapy (Figure 4B). It should be noted
that after the CA/DC-IT therapy, the mean fluorescence intensity
(MFI) of gp70 tetramer binding was also increased in the CD8+
cells of F10-mock(+) mice (from 673 to 1003), while remaining
low in the CD8+ cells of H6(+) mice (from 261 to 331), indicating
almost no induction of tumor-specific CD8+ cells with high T cell
receptor avidity. In the H6(+) mice receiving the therapy,
CD4+Foxp3+ cells were decreased in the regional lymph nodes,
but not in spleens and peripheral blood, and no increase of gp70
tetramer-binding CD8+ cells was observed systemically in these
peripheral tissues (Table S2). When splenic T cells from these
mice were stimulated with anti-CD3 mAb and APCs in vitro for
5 days, the proliferative ability of both CD4+ and CD8+ cells
was significantly augmented in F10-mock(+) mice after CA/DC-
IT therapy (p < 0.01; Figure 4C). However, splenic T cells from
H6(+) mice did not proliferate even after the therapy. Interest-
ingly, H6-snail+ tumor cells were resistant to cytolysis by gp70-
specific cytotoxic T lymphocytes (CTLs), which demonstrated
higher cytotoxicity to mock tumor cells (Figure 4D). These results
indicate that Snail+ melanoma cells are resistant to immuno-
therapy due to both inhibition of antitumor immune induction
via immunosuppression and decreased sensitivity to CTL lysis.
To clarify the relationship between tumors with Snail
increased by naturally occurring EMT and immunoresistance,
we further conducted the same CA/DC-IT therapy using mice
implanted with B16-F10 tumor cells with high Snail expressionCancer Cell 15, 195–206, March 3, 2009 ª2009 Elsevier Inc. 199
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Figure 5. Abrogation of Snail+ Tumor-
Induced Immunosuppression In Vivo by
Intratumoral Injection with snail-Specific
siRNA
(A) Inhibition of H6-snail+ tumor growth by snail-
specific siRNA injection. C57BL/6 mice received
i.t. injection with PEI-complexed snail-specific
siRNA #2 or scrambled oligonucleotide control
on day 7 after tumor implantation and were sacri-
ficed for assays on day 14 (n = 3–5, mean).
(B) Inhibition of systemic micrometastasis of
H6-snail+ tumor cells by siRNA-snail. Melanoma
antigen gp100 mRNA was detected by RT-PCR.
PB, peripheral blood; BM, bone marrow; SP,
spleen; LG, lung; TU, tumors subcutaneously im-
planted; vitro, either mock or H6-snail+ tumor cells
cultured in vitro as a control for gp100.
(C) Increased infiltration of CD4+ cells, CD8+ cells,
and CD11c+I-Ab+ cells in tumor tissues injected
with siRNA-snail. The percentage of each positive
fraction was analyzed by flow cytometry. The
numbers in parentheses indicate the Foxp3 MFI
of CD4+Foxp3+ cells (upper histograms) or the
gp70 tetramer MFI of gp70 tetramer-binding
CD8+ cells (lower histograms). To analyze T cells
infiltrating into H6-snail+ tumors, 1 3 104 CD3+
cells were acquired to analyze Foxp3+ expression
in CD4+ cells or gp70 tetramer-binding CD8+ cells
because these contain very few CD3+ cells in the
tumor-infiltrating lymphocytes.
(D) Augmentation of splenic T cell proliferation by
siRNA-snail injection (n = 3, mean ± SD).
(E) Enhancement of IFN-g production from splenic
CD8+ cells specific for melanoma antigen gp70
and gp100 by siRNA-snail injection (n = 3,
mean ± SD).
(F) Restoration of APC activity of bone marrow-
derived CD11c+ cells on splenic T cell proliferation
by siRNA-snail injection (n = 3, mean ± SD).
Data shown in each panel are representative of
three independent experiments.and high invasive ability after treatment with TGF-b for 3 days as
shown in Figure 2G. When TGF-b-treated tumor cells as well as
Snail transfectants were implanted both s.c. and i.v. in C57BL/6
mice, the growth was slower (Figure S4A), metastasis to lungs
was increased (Figure S4B), and tumor-infiltrating cells were
less numerous (Figure S4C) compared to those of TGF-b()
tumors (significant difference, p < 0.0001). When the TGF-b(+)
tumors were treated with the CA/DC-IT therapy on day 5 after
tumor implantation, the therapeutic effect was apparently less
than on the TGF-b() tumors, although showing a significant
tumor-suppressive effect on day 14 (p < 0.0003; Figures S4A–
S4B). The pattern of T cell infiltration into the treated TGF-b(+)
tumors was similar to the case of H6-snail+ tumors, in which
T cells were only slightly increased by the therapy (Figure S4C).
These results indicate that naturally occurring EMT is also asso-
ciated with resistance to immunotherapy.
Induction of Antitumor Immune Responses
by Targeting snail
We then attempted to abrogate the immunosuppression by
targeting snail. Although H6-snail+ tumors grew significantly
less than the mock-transfected tumors (p < 0.001; Figure 5A),200 Cancer Cell 15, 195–206, March 3, 2009 ª2009 Elsevier Inc.as was the case in vitro (Figure 1C), gp100, representative of
micrometastasis of the B16-F10 tumor cells, was detected in
various organs including peripheral blood, bone marrow,
spleens, and lungs of the mice on day 14 (Figure 5B, middle
panel), while being only faintly detected in spleens and lungs of
mice with mock-transfected tumors (Figure 5B, upper panel),
indicating more spontaneously metastatic ability of the Snail+
tumors even by s.c. implantation. When polyethyleneimine
(PEI)-complexed siRNA specific for murine snail was injected
i.t. into H6-snail+ tumors on day 7, tumor growth was signifi-
cantly inhibited as compared with control scrambled siRNA
(p < 0.001; Figure 5A), as well as tumor metastasis (Figure 5B,
lower panel). Survival of mice was significantly prolonged by
the siRNA-snail injection when observed over a longer term
(p < 0.008; mean survival: 15 days for control mice versus
35 days for siRNA-snail mice). In the H6-snail+ tumors treated
with snail-specific siRNA, infiltration of immune cells such as
CD4+, CD8+, and CD11c+ cells was markedly increased as
compared to that in the control H6-snail+ tumors (Figure 5C).
Foxp3 was reduced in the CD4+ cells, gp70 tetramer binding
was increased in the CD8+ cells, and I-Ab was enhanced in the
CD11c+ cells. As compared with F10-mock(+) mice, splenic
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Figure 6. Restoration of Antitumor Effector
Cells in Snail+ Tumors Injected with Anti-
TSP1 Monoclonal Antibody
(A) Inhibition of H6-snail+ tumor growth by anti-
TSP1 mAb injection. C57BL/6 mice received intra-
tumoral injection with anti-TSP1 mAb or isotype
control mIgG on day 7 after tumor implantation
and were sacrificed for assays on day 14 (n = 3,
mean).
(B) Inhibition of systemic micrometastasis of H6-
snail+ tumor cells by siRNA-snail. Melanoma
antigen gp100 mRNA was detected by RT-PCR.
LG, lung; SP, spleen; PB, peripheral blood;
BM, bone marrow; TU, tumors subcutaneously
implanted.
(C) Increased infiltration of CD4+ cells, CD8+ cells,
and CD11c+I-Ab+ cells in tumor tissues injected
with anti-TSP1mAb. The percentage of each posi-
tive fraction was analyzed by flow cytometry. The
numbers in parentheses indicate the Foxp3 MFI
of CD4+Foxp3+ cells (upper histograms) or the
gp70 tetramer MFI of gp70 tetramer-binding
CD8+ cells (lower histograms).
Data shown in each panel are representative of
two independent experiments.T cells proliferated significantly less (p < 0.003; Figure 5D), CD8+
T cells produced less IFN-g in response to the tumor antigen
peptides gp70 and gp100 (p < 0.01; Figure 5E), and CD11c+
BMCs induced less T cell proliferation (p < 0.001; Figure 5F) in
the H6(+) mice. CD8+ T cell responses were particularly impaired
in the H6(+) mice. However, all of these antitumor immune
responses were restored by i.t. injection of siRNA-snail into
H6-snail+ tumors (p < 0.001; Figures 5D–5F). These results indi-
cate that Snail+ melanoma cells induce in vivo immunosuppres-
sion through induction of CD4+Foxp3+ Treg cells and impaired
DCs as observed in vitro. Such immunosuppression could inhibit
induction of antitumor immune responses and accelerate tumor
metastasis. This suggests that snail-targeting therapy could
augment antitumor immune responses by abrogating tumor-
induced immunosuppression.
TSP1 Is Involved in Snail-Induced Immunosuppression
We next attempted to determine the mechanisms for the Snail-
induced immunosuppression in vivo by focusing on TSP1,
because TSP1 was most significantly increased in snail-trans-
duced B16-F10 melanoma (Figure 2E) and because anti-TSP1
mAb most strongly inhibited CD4+Foxp3+ Treg induction by
the Snail transfectants as compared with other Treg-inducible
cytokines (Figure 2F). H6-snail+ tumor growth and metastasis
were significantly inhibited by i.t. injection with anti-TSP1 mAb
on day 7 as compared with mice injected with the isotype control
(p < 0.03; Figures 6A and 6B). Survival was significantly pro-
longed by the anti-TSP1 mAb injection when observed over
a longer term (p < 0.0001; 16 days for mIgG(+) mice versus
28 days for anti-TSP1 mAb(+) mice). When anti-TGF-b mAb
was injected, since TSP1 is known to be a TGF-b activator, no
antitumor effect was observed, at least at the same dose of
anti-TSP1 mAb, suggesting that TSP1 would be a more potent
effector molecule than TGF-b in the Snail-induced immunosup-pressive mechanism (data not shown). Infiltration of immune
cells, including CD4+ cells with reduced Foxp3, CD8+ cells with
greater binding of gp70 tetramer, and I-Ab+CD11c+ DCs, was
markedly increased in the anti-TSP1 mAb-injected tumors
(Figure 6C). The amount of immune cells, particularly DCs, was
more increased in these tumors, while the mAb efficacies to
decrease Treg cells and expand tumor-specific CD8+ cells
were inferior to those induced by snail-specific siRNA (Figure 5),
implying the possibility that another molecule could be also
involved in Snail-induced immunosuppression. However, these
results indicate that TSP1 is one of the key mediators involved
in Snail-induced immunosuppression. Further study will be
required to identify the additional molecules involved.
It should be noted that i.t. injection with snail-specific siRNA or
anti-TSP1 mAb more effectively inhibited growth of the mock
transfectants with low Snail, and the treated tumors disappeared
in some of these mice (p < 0.0001; Figure 5A; Figure 6A),
following increased infiltration of immune cells such as CD4+
cells with low Foxp3, gp70 tetramer-binding CD8+ cells, and
mature DCs, similar to our observations when snail-transduced
tumor were injected i.t. (Figure 5C; Figure 6C). The survival of
these mice was also significantly prolonged when observed
over a longer term (p < 0.0001; 24 days for control mice versus
48 days for siRNA-snail mice and 34 days for anti-TSP1
mAb(+) mice). These data indicate that immunosuppression
in vivo might also be caused by tumor cells with low levels of
endogenous Snail expression.
Induction of CD4+Foxp3+ Cells by snail-Transduced
Human Melanoma Cells with EMT-like Features
We then evaluated whether Snail-induced immunosuppression
would be caused similarly by human melanoma. The human
melanoma cell line HS294T transduced with the human snail
gene showed typical EMT features such as spindle and dendriticCancer Cell 15, 195–206, March 3, 2009 ª2009 Elsevier Inc. 201
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increased cell invasion accompanied by decreased E-cadherin
and increased fibronectin (Figures 7A–7C). Also, these transfec-
tants showed increased mRNA expression of TGF-b, IL-10, and
TSP1. When human peripheral blood mononuclear cells
(PBMCs) were cocultured with one of the Snail transfectants,
D9-snail+, CD4+CD25+ cells were slightly increased and
FOXP3 expression in the CD4+ cells was significantly increased
(p < 0.01; Figure 7D; Table S1). CD11c+HLA-DR+ cells were less
numerous as compared with those cocultured with the mock-
transfected HS294T cells (Figure 7D). When TSP1 was added
to the culture with mock-transfected tumor cells and PBMCs,
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Figure 7. Immunosuppression Induced by snail-Transduced
HumanMelanomaHS294TCellswithEMT-likeCharacteristics
(A) Left: decrease of the epithelial marker E-cadherin and increase of
the mesenchymal marker fibronectin and immunosuppressive
cytokines (TGF-b, IL10, and TSP1) in the Snail transfectants detected
by RT-PCR. Right: the intensity of snail, E-cadherin, and fibronectin
was normalized to GAPDH expression as a control.
(B) Decrease of E-cadherin and increase of fibronectin in the Snail
transfectants with spindle and dendritic shapes (immunocytochem-
istry; scale bars = 0.5 mm).
(C) EMT-like functional changes of Snail transfectants: decreased
proliferation, decreased adhesion, and increased invasion (n = 3,
mean ± SD).
(D) Increase of CD4+Foxp3+ cells and decrease of CD11c+HLA-DR+
cells induced by D9-snail+ tumor cells. Human peripheral bloodmono-
nuclear cells (PBMCs) were cocultured with tumor cells with or without
TSP1 or anti-TSP1 mAb for 5 days. The percentage of each positive
fraction was analyzed by flow cytometry.
Data shown in each panel are representative of two independent
experiments.
Treg induction was increased and mature DC induction
was inhibited (Figure 7D). Conversely, Treg induction
was significantly decreased (p < 0.014; Table S1) and
mature DC induction was markedly increased when anti-
TSP1 mAb was added to the culture with D9-snail+ tumor
cells and PBMCs (Figure 7D). These data also suggest
TSP1 involvement in the immunosuppression induced
by human Snail+ melanoma. In addition, such immuno-
suppressive effects were similarly induced by other
snail-transduced melanoma cell lines and other types of
cancer cell lines such as pancreatic cancers or colon
cancers (data not shown). These results indicate that
human Snail+ cancer cells induce immunosuppression
as well as murine Snail+ melanoma cells.
Induction of EMT and Immunosuppression
by Endogenous Snail Is Increased by TGF-b
Treatment in Human Melanoma Cells
We further examined the relationship between naturally
occurring EMT in tumor cells and immunosuppression
using various human melanoma cell lines. When human
PBMCs were cocultured with melanoma cells with or
without TGF-b, the level of CD4+Foxp3+ cell induction
was correlated with snail expression induced by TGF-b
(Figure 8A). Similar results were also observed in
ARPE19 retinal pigment epithelial cells treatedwith TGF-b,
suggesting that immunosuppression could also be caused by
Snail-induced EMT even in noncancerous cells. CD4+FOXP3+
cells were not increased when cocultured with siRNA-snail(+)
melanoma cells even after TGF-b treatment (Figure 8B), possibly
because TSP1 production from melanoma cells was reduced at
the same time that tumor invasion was suppressed by siRNA-
snail transfection (Figure 8C), suggesting that the increased
endogenous Snail could be correlated with induction of both
EMT and immunosuppression in various humanmelanoma cells.
These results indicate that the data obtained using snail-trans-
duced melanoma cells reflect the naturally occurring, Snail-
induced EMT.202 Cancer Cell 15, 195–206, March 3, 2009 ª2009 Elsevier Inc.
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EMT accelerates melanoma metastasis through not only
enhanced invasive ability but also severe immunosuppression
mediating induction of immunosuppressive cytokines and
generation of Treg cells and impaired DCs. Therefore, snail-
targeting therapy could simultaneously inhibit both cancer
metastasis and immunosuppression including multiple suppres-
sive molecules and/or cells in cancer patients.
DISCUSSION
EMT is thought to be a key step toward tumor metastasis via
induction of highly invasive cancer cells, and its molecular mech-
anisms have been intensively studied. However, how cancer
cells influence the host immune system during EMT is unclear.
In this study, we demonstrate that Snail-induced EMT acceler-
ates tumor metastasis via both enhanced invasive ability and
immunosuppression. Snail+ melanomawith typical EMT features
severely induced immunosuppression both in vitro and in vivo.
Notably, almost no infiltration of antitumor effector cells was
observed in the local tumor sites in vivo, and almost no CD8+
responses specific for tumor antigens were induced, resulting
in enhanced tumor metastasis in various organs of the mice
implanted s.c. with Snail+ tumors. These events could possibly
be mediated by induction of Treg cells with high Foxp3
expression and impaired DCs with low costimulatory molecule
expression but high IDO expression, as observed in vitro.
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Figure 8. Induction of CD4+Foxp3+ Cells by Human Mela-
noma Cells with High Invasive Ability after TGF-b Treatment
(A) Increase of CD4+Foxp3+ cells in human PBMCs correlates with
snail expression in human melanoma or normal cells cocultured
together for 5 days.
(B) Inhibition of CD4+Foxp3+ cell induction by snail knockdown in
HS294T melanoma cells after transfection with snail-specific siRNA.
Top: snail mRNA expression analyzed by RT-PCR. Bottom: Foxp3
induction in CD4+ cells analyzed by flow cytometry. The numbers in
parentheses indicate the Foxp3 MFI of CD4+Foxp3+ cells.
(C) Inhibition of cell invasion and TSP1 production of HS294T
melanoma cells by transfection with snail-specific siRNA (n = 3,
mean ± SD). Melanoma cells or normal ARPE19 epithelial cells treated
with TGF-b (5 ng/ml) for 3 days were used after washing for assays.
Data shown in each panel are representative of two independent
experiments.
Snail+ melanoma cells appear to generate immuno-
suppressive nTreg-like CD4+CD25 cells rather than to
increase CD4+CD25+ nTreg cells, partly by mediating
Treg-inducible cytokines such as TGF-b and TSP1. In addi-
tion to the direct effect of these cytokines, impaired DCs
with low costimulatory molecule expression and high IDO
(an immunosuppressive enzyme that acts via tryptophan
deficiency) generated by Snail+ melanoma cells are indi-
rectly important for the induction of nTreg-likeCD4CD25
cells ina cell-cell contactmanner. TSP1 is thought tobeone
of the major factors involved in in vitro and in vivo immuno-
suppression; however, other immunosuppressive mecha-
nisms may be also involved in the Snail-induced events,
since the production level of the immunosuppressive
factors appears to be different among various cancer cells.
This study reveals that Snail+ melanoma is resistant to DC-
based immunotherapy (CA/DC-IT), which is usually effective in
suppressing Snail B16-F10 melanoma followed by induction
of antitumor immune responses. No antitumor T cell responses
were induced in mice with Snail+ melanoma even after the CA/
DC-IT therapy because of Snail-induced immunosuppression
mediated by nTreg-like CD4+Foxp3+ cells and impaired DCs.
Additionally, Snail+ melanoma itself was resistant to CTL lysis.
EMT of tumor cells is reportedly associated with resistance
to chemotherapeutics such as paclitaxel and gemcitabine
(Kajiyama et al., 2007; Shah et al., 2007).We also observed resis-
tance of our Snail transfectants to 5-fluorouracil, cyclophospha-
mide, and paclitaxel, as previously reported by others (data not
shown). In this study, we demonstrate that Snail-induced EMT
also renders melanoma cells resistant to CTL attack as well as
to chemotherapeutics.
These findings obtained with the snail-transduced melanoma
are applicable to the naturally occurring Snail-induced EMT.
Both the invasive ability and the Treg-inducible ability of human
melanoma cells are correlatively enhanced by endogenous Snail
increase after TGF-b treatment, and both abilities were abro-
gated by snail-specific siRNA transfection (Figure 8). In addition,
injection with snail-specific siRNA was also effective in inhibiting
mock transfectants with low expression of endogenous Snail
(Figure 5). Snail-induced immunosuppressive cascades would
be applicable for patients with various cancers because such
phenomena have been similarly induced by other human cancerCancer Cell 15, 195–206, March 3, 2009 ª2009 Elsevier Inc. 203
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and colorectal cancers (data not shown). Thus, our study
demonstrates that cancer EMT and immunosuppression can
be simultaneously induced by Snail, which is predominantly
involved in EMT induced by various stimuli in a variety of human
cancers. However, it is not clear whether both are necessarily
induced together or whether each event is induced separately.
Further studies including analysis of EMT regulated by other
transcription factors such as Slug and Twist are required.
Recently, many other studies have been reported involving
a variety of immunosuppressivemolecules such as TGF-b, IL-10,
VEGF, and IL-6 and a variety of immunosuppressive cells such
as CD4+ Treg cells, CD8+ Treg cells (Bisikirska et al., 2005; Rifa’i
et al., 2004), natural killer T cells (Kronenberg and Rudensky,
2005), gd cells (Koshiba et al., 2007), tumor-associated macro-
phages (Porta et al., 2007), and myeloid-derived suppressor
cells (Talmadge, 2007). Correlation between increases in these
suppressive factors and poor patient prognosis (Beyer and
Schultze, 2006; Rouse, 2007; Waldmann, 2006) has been
demonstrated. Based on recent progress in human tumor immu-
nology, various active immunization trials have been attempted
in cancer patients (Rosenberg et al., 2004). However, the effi-
cacy of these trials has been limited so far. One of the major
problems is thought to be systemic and local immunosuppres-
sion mediated by known and unknown mechanisms in cancer
patients. The comprehensive inhibition of these multiple immu-
nosuppression factors will be required for improvement of anti-
tumor immune responses in cancer patients. In this study, snail
knockdown in Snail+ melanoma using snail-specific siRNA
abrogated Snail-induced effects, both tumor metastasis and
immunosuppression, followed by tumor inhibition along with
local infiltration of antitumor effector cells in tumor tissues and
systemic induction of tumor-specific CD8+ T cell responses
in vivo. Inhibition of the EMT upstream molecule Snail could be
effective in simultaneously blocking both cancer invasion and
immunosuppression. This strategy would be an attractive
approach to improving the antitumor efficacies of a variety of
cancer therapies.
EXPERIMENTAL PROCEDURES
Cell Lines and Mice
Murine melanoma cell line B16-F10; human melanoma cell lines HS294T,
A375mel, 526mel, and 1363mel; and human retinal pigment epithelial cell
line ARPE19 were used. Female C57BL/6 mice were purchased from SLC
(Japan) and maintained under pathogen-free conditions until used for experi-
ments. Mice were used upon approval by the Animal Care and Use Committee
of Keio University School of Medicine. In some experiments, cells were treated
with TGF-b, TNFa, or TSP1 (5 ng/ml) for 3 days to induce EMT.
snail Gene Transfection
Tumor cells were transfected with plasmid vector pcDNA3.1(+) (Invitrogen)
encoding either murine or human snail cDNA or with the empty vector as
mock transfection by electroporation (0.4 kV, 25 microfaradays) and selected
with G418 in 10% FCS-containing DMEM. Cells were trypsinized and washed
in PBS before use in assays.
RT-PCR
Each cDNA was synthesized with an oligo(dT) primer from total RNA extracted
from cells using an RNeasy kit (QIAGEN) according to the manufacturer’s
instructions and was amplified with specific paired primers and Ex Taq poly-
merase (Takara) by PCR as follows: denaturation at 94C for 30 s, 30 cycles204 Cancer Cell 15, 195–206, March 3, 2009 ª2009 Elsevier Inc.of annealing at 55C–65C for 30 s, and elongation at 72C for 60 s. The
primers used for detection of murine and human gene expression are shown
in Table S3. Digital images of the bands were analyzed and quantified using
NIH ImageJ software (http://rsb.info.nih.gov/ij/), and each signal intensity
was normalized to GAPDH expression as a control.
Immunocytochemistry
To analyze expression and localization of specific proteins in cells, tumor cells
were prepared by culture in a slide chamber for 24 hr or by cytospin before
staining. After treatment with Cytofix/Cytoperm solution (BD Pharmingen),
tumor cells were stained with anti-Snail mAb (Santa Cruz Biotechnology),
anti-E-cadherin mAb (BD Pharmingen), anti-fibronectin mAb (R&D Systems),
or the appropriate isotype control antibodies. Alexa 488 (green)- or Alexa
568 (red)-conjugated secondary antibodies (Invitrogen) were used for visuali-
zation, and cells were observed using a confocal LSM 5 Pascal microscope
(Carl Zeiss Meditec).
Functional Characterization of Tumor Cells
To evaluate cell adhesion, tumor cells (4 3 104 cells/well) were cultured in
fibronectin-coated 96-well plates (BDBiosciences) for 1 hr at 37C (n = 3). After
vigorous vortexing for 30 s, the nonadherent cells were discarded and treated
with a fixation/staining solution containing 0.5% crystal violet, 12% formalde-
hyde, and 10% ethanol for 15 min. After washing in water and then drying, 1%
SDS solution (100 ml/well) was added, and the extract absorbance was
measured at 570 nm. To evaluate cell invasion, 43 104 cells/well were cultured
in 1% BSA/PBS in the upper compartment of a transwell chamber with a Ma-
trigel-coated membrane (pore size = 8 mm; BD Biosciences) using 24-well
plates for 16 hr at 37C (n = 3). After scraping cells on the surface using cotton
swabs, the membrane was treated with the fixation/staining solution, and the
invaded cells were counted under a microscope. To evaluate cell proliferation,
23 104 cells/well were cultured in 96-well flat-bottom plates for 3 days at 37C
(n = 3), and WST-1 solution (Takara) was added into each well. After additional
culture for 3–4 hr, absorbance was measured at 450–655 nm. Cytokine
production from tumor cells (3-day culture) was measured using ELISA kits
(TGF-b and IL-10, R&D Systems; TSP1, Chemicon) according to the manufac-
turers’ instructions. To evaluate in vivo tumor growth, 13 106 tumor cells were
implanted s.c. into the right flank of C57BL/6 mice. Tumor size was measured
1–2 times per week, and the volume in mm3 was calculated as follows:
0.5 3 length 3 width2. To evaluate the in vivo metastatic ability of tumor cells
andmouse survival after tumor implantation, 23 105 tumor cells were injected
i.v. in the tail vein of mice.
In Vitro Stimulation of Immune Cells with Tumor Cells
In the murine system, spleens were pooled and dispersed into single-cell
suspensions, and SPCs were isolated by Ficoll-Paque (Amersham) followed
by treatment with ACK solution (BioWhittaker). 13 106 SPCs were stimulated
with 13 105 irradiated or mitomycin C (MMC)-treated tumor cells in 10% FCS-
containing RPMI1640 (37C, 5% CO2) for 5 days. In some experiments, SPCs
were separated into specific cell populations (CD4+ or CD11c+) utilizing
a magnetic-activated cell sorting separation system with mAb-conjugated Mi-
croBeads according to themanufacturer’s instructions (Miltenyi Biotec) and/or
separately cultured using a transwell chamber with a membrane (pore size =
0.4 mm; Cell Culture Insert, Becton Dickinson). For DC analysis, 1 3 106
BMCs from femurs after Ficoll isolationwere separated into CD11c+ cells using
anti-CD11cmAb-conjugatedMicroBeads, and the CD11c+ cells were cultured
with GM-CSF (10 ng/ml, PeproTech) and/or irradiated tumor cells (10:1) for
6 days. To evaluate TSP1 effects on DCs, the purified CD11c+ cells were stim-
ulated with TSP1 (0.5 mg/ml, R&D Systems) for 5 days. To block IDO induction
in the DCs, the IDO inhibitor 1-methyltryptophan (1MT, Sigma) was added at
1 mM to the culture. Anti-TSP1 (Calbiochem), anti-CD36 (Abcam), or anti-
CD47 mAb (BD Pharmingen) was added to the culture to examine the involve-
ment of these receptors in the TSP1-induced mechanism.
In the human system, human peripheral blood cells from healthy volun-
teers were also isolated by Ficoll-Paque followed by treatment with ACK
solution. The mononuclear cells (PBMCs) at the interface between blood
and Ficoll-Paque solution were harvested, and these PBMCs (1 3 106 cells)
were stimulated with 1 3 105 irradiated or MMC-treated tumor cells or the
supernatant (3-day culture, 23 dilution) at 37C for 5 days. For DC analysis,
Cancer Cell
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gated MicroBeads were cultured with irradiated tumor cells (10:1) for
5 days. To block the specific cytokine in the culture, mAbs specific for
TGF-b (R&D Systems), IL-10 (R&D Systems), or TSP1 (Calbiochem) were
added at 2–5 mg/ml.
Flow Cytometric Analysis
To examine tumor cell effects on immune cells in vitro and in vivo, specific
markers were analyzed by flow cytometry. Fc receptor was blocked by anti-
CD16/CD32 mAb before immunofluorescence staining. The following anti-
bodies conjugated with FITC, phycoerythrin, or CyChrome were used for
analysis: anti-Foxp3, anti-CD4, anti-CD25, anti-CTLA4, anti-HO-1, anti-gran-
zyme B, anti-PD1, anti-CD8, anti-CD11c, anti-I-Ab, anti-CD80, anti-IDO,
anti-HLA-DR, or the appropriate isotype-matched control antibodies. Anti-
bodies and isotype controls were purchased from BD Pharmingen, except
anti-Foxp3 mAb (eBioscience), anti-HO-1 (Abcam), anti-granzyme B (eBio-
science), and anti-IDO mAb (Serotec). For intracellular staining of Foxp3,
CTLA-4, HO-1, granzyme B, and IDO, cells were treated with Cytofix/Cyto-
perm solution (BD Pharmingen) according to the manufacturer’s instructions.
The immunofluorescence was compared to the appropriate isotype controls
and analyzed with CellQuest software using a FACSCalibur cytometer (Becton
Dickinson).
Immunosuppressive Activity of CD4+ Cells and DCs
To evaluate the immunosuppressive activity of CD4+ cells stimulated with
tumor cells, CD4+ cells were separated from the cultured spleen cells after
stimulation with Snail transfectants for 5 days. The prestimulated CD4+ cells
were added to the culture with fresh and purified splenic CD4+ or CD8+ cells
at a 1:1 ratio in addition to APCs (irradiated bulk SPCs) and anti-CD3 mAb
(1 mg/ml) for 5 days (n = 3). To evaluate APC function of the BMC-derived
CD11c+ cells stimulated with tumor cells, the precultured CD11c+ cells were
added to fresh and purified splenic CD4+ or CD8+ cells (1:1) and cultured
with anti-CD3 mAb (1 mg/ml) for 5 days (n = 3). Cell proliferation was evaluated
by WST-1 assay.
RNA Interference Assay In Vitro and In Vivo
For snail knockdown in tumor cells, FITC-conjugated siRNAs (Invitrogen)
specific for murine or human snail were used in assays in vitro and in vivo after
the optimal transfection condition was determined initially. FITC-labeled
siRNA-snail or scrambled oligonucleotide control (Invitrogen) was diluted in
150mMNaCl andmixed with 7.5 mM jetPEI (Polyplus Transfection), a cationic
polymer transfection reagent useful for gene delivery in vitro and in vivo
(Urban-Klein et al., 2005). The complexes were incubated for 15 min and
then added to cells at 50%–60% confluence. Typically, 3 3 105 tumor cells
were seeded in six-well plates, 2 mg jetPEI/siRNA-snail was added 24 hr later,
and the cells used for assays within 2–6 days after transfection. The transfec-
tion efficacy was validated by flow cytometry before use; >80%–90% of the
cells were FITC positive. snail expression was evaluated by RT-PCR and
immunocytochemistry. For snail knockdown in vivo, jetPEI/siRNA-snail (3 mg)
was injected i.t. on day 7 after tumor implantation. The transfection efficacy
was validated by flow cytometry 1–2 days after injection; >60%–70% of the
cells were FITC positive in cells harvested from the injected tumors. snail
expression in the tumor sites was evaluated by RT-PCR using Ampdirect
Plus (Shimadzu) according to the manufacturer’s instructions.
Tumor Therapy In Vivo
C57BL/6 mice were implanted s.c. with B16-F10 tumor cells into the right flank
(13 106 cells/site) and received the following combination immunotherapy on
day 7 after tumor implantation (n = 5–7): tumors were cryoablated at80C for
60 s using a Keeler Cryomaster and then directly injected with DCs (2 3 106
cells/mouse), whichwere pulsedwith theH-2Kb-restricted peptide p15E604–611
(1mg/ml, KSPWFTTL, referredasgp70peptide) for 6 hr before use. In theexper-
iments using TGF-b-treated tumor cells, to evaluate the antitumor effect on
tumormetastasis,micewere implanted both s.c. at the right flank (13106 cells)
and i.v. in the tail vein (23105cells) and then received thesame immunotherapy
on day 5 after tumor implantation (n = 3–5). In the experiments to evaluate TSP1
blockade effect in vivo, tumors were directly injected with anti-TSP1 mAb
(50 mg/mouse) on day 7 after tumor implantation (n = 3). Mice were sacrificedon day 14, and tumors and other tissues (peripheral blood, bone marrow,
spleens, inguinal lymph nodes, and lungs) were harvested and mechanically
dispersed into single-cell suspensions for assays (n = 3–5, pooled). To examine
tumor micrometastasis in organs after s.c. tumor implantation, RT-PCR for
the melanoma antigen gp100 was conducted using specific primers with
Ampdirect Plus.
Evaluation of Tumor-Specific CD8+ T Cell Responses
To evaluate CD8+ T cell immune responses specific for tumor antigens, as
described previously (Kudo-Saito et al., 2005), SPCs were first stimulated
with 1 mg/ml of gp70 peptide or the H-2Db-restricted peptide gp10025–33
(KVPRNQDWL). Six days later, bulk lymphocytes were separated by Ficoll-Hy-
paque isolation, and the recovered CD8+ T cells were tested for cytokine
production and tumor-killing activity. In cytokine production assay, 5 3 105
recovered CD8+ T cells were restimulated with 5 3 106 fresh irradiated naive
splenocytes as APCs and 1 mg/ml peptide for 24 hr (n = 3), and the supernatant
fluid was analyzed for IFN-g using a Cytometric Bead Array kit (BD Pharmin-
gen). A small amount of IFN-g (less than 20 pg/ml) was detected in each
SPC culture supernatant with the control peptide (H-2Kb-restricted b-galacto-
sidase96–103, 1 mg/ml, DAPIYTNV) or no peptide (spontaneous production). In
cytotoxicity assay using an annexin V system (Immunocyto Cytotoxicity
Detection Kit, MBL), 13 105 target tumor cells were incubated with the recov-
ered CD8+ T cells for 4 hr (n = 3) and analyzed by flow cytometry according to
the manufacturer’s instructions.
Statistical Analysis
Significant differences (p < 0.05) were evaluated using the unpaired two-tailed
Student’s t test. For graphical representation of data, y axis error bars indicate
the standard deviation of the data for each point on the graph. Mouse survival
was evaluated by the Kaplan-Meier method and ranked according to the
Mantel-Cox log-rank test.
SUPPLEMENTAL DATA
The Supplemental Data include three tables and four figures and can be
found with this article online at http://www.cancercell.org/supplemental/
S1535-6108(09)00032-4.
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